David A Price

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2807767/publications.pdf

Version: 2024-02-01

41 papers	4,338 citations	257101 24 h-index	253896 43 g-index
44 all docs	44 docs citations	44 times ranked	6116 citing authors

#	Article	IF	Citations
1	A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. Journal of Medicinal Chemistry, 2022, 65, 8208-8226.	2.9	42
2	Ligand biological activity predicted by cleaning positive and negative chemical correlations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3373-3378.	3.3	26
3	Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules. Journal of Medicinal Chemistry, 2017, 60, 1665-1672.	2.9	112
4	Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. Organic and Biomolecular Chemistry, 2017, 15, 2501-2506.	1.5	20
5	Amine promiscuity and toxicology analysis. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 653-657.	1.0	9
6	Discovery of Potent and Orally Bioavailable Macrocyclic Peptideâ€“Peptoid Hybrid CXCR7 Modulators. Journal of Medicinal Chemistry, 2017, 60, 9653-9663.	2.9	54
7	Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK). Journal of Medicinal Chemistry, 2017, 60, 7835-7849.	2.9	35
8	Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European Journal of Medicinal Chemistry, 2017, 127, 703-714.	2.6	19
9	Chiral Sulfoxide-Induced Single Turn Peptide Î±-Helicity. Scientific Reports, 2016, 6, 38573.	1.6	22
10	Truncated Glucagon-like Peptide-1 and Exendin-4 Î±-Conotoxin pl14a Peptide Chimeras Maintain Potency and Î±-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. Journal of Biological Chemistry, 2016, 291, 15778-15787.	1.6	10
11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. Journal of Medicinal Chemistry, 2015, 58, 4581-4589.	2.9	112
12	Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. Journal of Medicinal Chemistry, 2015, 58, 4080-4085.	2.9	38
13	Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. European Journal of Medicinal Chemistry, 2015, 97, 202-213.	2.6	76
14	Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry, 2015, 103, 175-184.	2.6	20
15	Small molecules that promote regenerative repair for pancreatic and cardiovascular health. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5465-5471.	1.0	4
16	Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Medicinal Chemistry Letters, 2015, 6, 1128-1133.	1.3	33
17	Revisiting N-to-O Acyl Shift for Synthesis of Natural Product-like Cyclic Depsipeptides. Organic Letters, 2014, 16, 6088-6091.	2.4	11
18	Modulation of adipose tissue thermogenesis as a method for increasing energy expenditure. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 425-429.	1.0	11

#	Article	IF	Citations
19	Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed. ACS Medicinal Chemistry Letters, 2014, 5, 1148-1151.	1.3	55
20	The Future of Peptideâ€based Drugs. Chemical Biology and Drug Design, 2013, 81, 136-147.	1.5	1,483
21	Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists. Progress in Medicinal Chemistry, 2013, 52, 45-96.	4.1	13
22	Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7523-7529.	1.0	13
23	Optimized glucuronidation of dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD. MedChemComm, 2011, 2, 870.	3.5	7
24	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. Chemical Research in Toxicology, 2011, 24, 1345-1410.	1.7	569
25	Inhalation by design: Dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2759-2763.	1.0	17
26	Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5308-5312.	1.0	61
27	Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks. Annual Reports in Medicinal Chemistry, 2010, , 380-391.	0.5	71
28	Inhalation by Design: Novel Ultra-Long-Acting Î²₂-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup. Journal of Medicinal Chemistry, 2010, 53, 6640-6652.	2.9	72
29	Physicochemical drug properties associated within vivotoxicological outcomes: a review. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 921-931.	1.5	131
30	The discovery of adamantyl-derived, inhaled, long acting Î²2-adrenoreceptor agonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1280-1283.	1.0	34
31	Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4872-4875.	1.0	749
32	Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV. Current Topics in Medicinal Chemistry, 2008, 8, 1140-1151.	1.0	24
33	Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Polarization Ligands for the Human Ether-a-go-go-Related Gene (hERG) Channel. Journal of Medicinal Chemistry, 2007, 50, 2931-2941.	2.9	41
34	The discovery of long acting Î²2-adrenoreceptor agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4012-4015.	1.0	40
35	The discovery of indole-derived long acting Î²2-adrenoceptor agonists for the treatment of asthma and COPD. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6188-6191.	1.0	29
36	Progress in the Development of Inhaled, Long-Acting Î²2-Adrenoceptor Agonists. Annual Reports in Medicinal Chemistry, 2006, 41, 237-248.	0.5	8

#	Article	IF	Citations
37	The Discovery of Tropane-derived CCR5 Receptor Antagonists. Chemical Biology and Drug Design, 2006, 67, 305-308.	1.5	19
38	Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4633-4637.	1.0	82
39	The Discovery of CCR5 Receptor Antagonists for the Treatment of HIV Infection: Hit-to-Lead Studies. ChemMedChem, 2006, 1, 706-709.	1.6	33
40	Initial synthesis of UK-427,857 (Maraviroc). Tetrahedron Letters, 2005, 46, 5005-5007.	0.7	51
41	A Practical Synthesis of Piperidine-/Tropane-Substituted 1,2,4-Triazoles. Synlett, 2005, 2005, 1133-1134.	1.0	16